Vol. 99, Issue 1 | January 3, 2007 N E W S and helped develop informed-consent documents for NCI-sponsored cancer clinical trials. But that can change, as it has with informed consent. Forty years ago it was common to enroll patients in clinical trials without their knowledge, she said. Over time, institutional review boards and informed consent became an accepted and legally required part of the system, but Kass said that because reporting results to patients was not required, it did not become common practice. That attitude is now changing, she said.
For example, the National Cancer Cooperative Groups, which enroll more than half of patients in U.S. cancer clinical trials, has established guidelines for disclosure of clinical trial results to patients enrolled in its studies and issued recommendations on how to communicate with patients if trials close early for any reason. They suggest that the treating physician (or the physician's designee) tell the trial participant the reason for the closure, the potential consequences of the closure for the patient's health, and any changes in treatment or follow-up required as a result of the new information.
But " There is this perception that any communication about a trial is taboo, " said Ken Getz, cofounder of the Center for Information and Study on Clinical Research Participation, Dedham, Mass., a nonprofi t organization that studies clinical trial participation. " There is enough evidence to suggest that there are things we can do now to communicate to volunteers who are eager to just hear any news. We don't need to do more research on whether it makes sense to inform them. They already are telling us that they want that. "
Getz says most patients are not asking for extensive details about a drug. What volunteers want shortly after their trial has ended is a note saying that their participation was useful and that they will be sent information as results become publicly available. " There's been all this attention paid to fi lling trials but not on nurturing and reinforcing our appreciation for the people who have already been in our trials, " he said. " That is one of the new places where sponsors need to focus some energy and investment. "
Eli Lilly and Co. is one pharmaceutical company currently wrestling with how to publicly release results of clinical trials. It has established a Web site, Lillytrials.com, and in late 2005 pledged to post the results of all phase II -IV clinical trials within 1 year of trial completion or " as soon as possible " if there are signifi cant safety concerns on any open trials. The company does not communicate results directly to patients who participate in trials but rather focuses on improving communication with particiwondered whether patients who had not received trastuzumab would have anxiety about their risk of recurrence when told the result. The research team sent surveys to all 228 trial participants and received responses from 160. Nearly all respondents reported that they were glad to have received the information, with 81% of the women satisfi ed with how results were shared. However, 63% of women reported that learning the results affected their lives, with 24% saying the results made them more anxious about their health. The study suggests that patients want results, she said, but investigators ought to think carefully about the impact that learning results, particularly negative results, could have on patients. " It's not a no-brainer, " she said. " I think it's the right thing to do, but I think it's something we have to do carefully. "
Wolff said there are already excellent examples of how to inform patients of trial results. He points to the MA.17 clinical trial, which tested whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduced the risk of breast cancer recurrence. The trial was halted early after an interim analysis showed that letrozole improved dis easefree survival (J Natl Cancer Inst 2005; 97: 1262 -71 ) .
Study coordinators sent out a mass email to study sites 3 days before publicly announcing that the trial was being stopped. The notice included a memo to patients including information that all enrolled patients would be offered open-label access to letrozole. The advance notice allowed Wolff's research nurse to contact all patients enrolled at Hopkins and answer any questions before the results became public.
Wolff said the medical community is often skeptical of major changes to accepted practice, and more research may be needed to convince clinicians that giving patients results of clinical trials can be done without unduly burdening the system.
But patient advocates say the process does not have to be complicated. Physicians and trial sponsors often project expecta- " I think that it is realistic to have a process in place that will allow participants, if they so desire, to view the results, " she said.
Kass said she believes the clinical research enterprise is entering a new phase in examining its responsibility to clinical trial participants. " There were some researchers who were kicking and screaming about the huge delays [in formed consent] would impose on their research. … But sometimes you have to do things, not because they are the most effi cient, but because they are right, " she said.
